Guideline for Cervical Ripening and Labor Induction in the Third Trimester of Pregnancy

Obstetrics Group, Society of Obstetrics and Gynecology, Chinese Medical Association

Labor induction in the third‑trimester pregnancy refers to the initiation of labor by pharmacological and other interventions prior to spontaneous labour onset to achieve delivery. It is one of the commonly‑used obstetric interventions for high‑risk pregnancies. The success of labor induction largely depends on cervical ripeness. Improper application may jeopardize maternal and fetal health. Therefore, indications for induction must be strictly followed and procedures standardized to reduce complication rates.

The Obstetrics Group, Society of Obstetrics and Gynecology, Chinese Medical Association published the Guideline (Draft) for Cervical Ripening and Labor Induction in the Third Trimester of Pregnancy in 2008. Based on that draft and combined with recent domestic and international evidence‑based medical data, substantial revisions have been made to provide evidence‑based recommendations for cervical ripening and labor induction in late pregnancy.

Ⅰ. Major Indications for Labor Induction

1. Prolonged pregnancy Induction shall be offered to women with pregnancy reaching 41 weeks or post‑term pregnancy, to reduce perinatal mortality and the incidence of meconium aspiration syndrome which contributes to higher cesarean‑section rates (Ⅰ‑A).
2. Hypertensive disorders of pregnancy Indication applies to: gestational hypertension and mild pre‑eclampsia at ≥37 weeks of gestation; severe pre‑eclampsia at ≥34 weeks, or with poor response to conservative management or disease deterioration; women with eclampsia after seizure control without spontaneous labour onset and fulfilling criteria for vaginal delivery.
3. Maternal severe comorbidities requiring early pregnancy termination Women with medical disorders such as diabetes, chronic hypertension and nephropathy who are capable of tolerating vaginal delivery.
4. Premature rupture of membranes (PROM) Women at term with premature rupture of membranes for more than 2 hours without labour onset.
5. Fetal and fetal‑appendage‑related factors Fetal conditions: severe fetal growth restriction (FGR), fetal death, and severe fetal malformations. Appendage‑related conditions: oligohydramnios; biochemical or biophysical profiles suggestive of placental insufficiency, while the fetus can still tolerate uterine contractions.

Ⅱ. Contraindications to Labor Induction

2.1 Absolute Contraindications

(1) Severe maternal comorbidities or complications precluding tolerance or feasibility of vaginal delivery (e.g. heart failure, severe hepatic‑renal disease, severe pre‑eclampsia complicated by organ injury). (2) Previous uterine surgery: classical cesarean section, cesarean section with unknown uterine incision, myomectomy penetrating the endometrium, history of uterine rupture, etc. (3) Complete or partial placenta previa, vasa previa. (4) Significant cephalopelvic disproportion precluding vaginal delivery. (5) Abnormal fetal presentation: transverse lie; nulliparous breech presentation with anticipated difficult vaginal delivery. (6) Cervical carcinoma. (7) Certain genital‑tract infectious diseases, e.g. untreated active genital herpes simplex virus infection. (8) Untreated HIV infection. (9) Hypersensitivity to induction agents. (10) Genital‑tract malformation or surgical history resulting in abnormal soft tissues or birth‑canal obstruction with anticipated difficult vaginal delivery. (11) Severe placental insufficiency where the fetus cannot tolerate vaginal delivery. (12) Prolapsing umbilical cord or occult umbilical‑cord prolapse.

2.2 Relative Contraindications

(1) Breech presentation (when vaginal‑delivery criteria are met). (2) Polyhydramnios. (3) Twin or multiple gestation. (4) Multiparae with ≥5 deliveries.

Ⅲ. Pre‑induction Preparation

1. Carefully verify induction indications and expected date of confinement To prevent iatrogenic preterm birth and unnecessary induction.
2. Assess fetal maturity If fetal lung immaturity is confirmed and clinical conditions permit, fetal lung maturation should be achieved prior to induction.
3. Detailed pelvic assessment Evaluate pelvic size and configuration, fetal size, fetal presentation, cephalopelvic relationship, and rule‑out contraindications for vaginal delivery.
4. Fetal surveillance Cardiotocography and ultrasonography shall be performed before induction to evaluate intrauterine fetal status.
5. Comorbidity evaluation For women with medical comorbidities or obstetric complications, disease severity and risks of vaginal delivery shall be fully assessed, relevant tests completed, and a detailed management plan formulated.
6. Requirements for medical staff Clinicians shall be proficient in various induction modalities as well as early recognition and management of associated complications. Labour progress shall be closely monitored with comprehensive documentation. Personnel and equipment for operative vaginal delivery and cesarean section shall be available throughout induction.

Ⅳ. Methods for Cervical Ripening

Cervical ripening aims to soften, efface and dilate the cervix, lower induction failure rates, and shorten the interval from induction to delivery. Cervical‑ripening interventions are indicated when induction is warranted but cervical conditions are unfavourable. Nulliparous women undergoing induction with an unripe cervix have a two‑fold higher risk of cesarean delivery (Ⅱ‑2). In addition, labour progress following induction is significantly slower than spontaneous labour (Ⅱ‑2)[7]. Clinicians shall assess cervical ripeness to select appropriate induction methods and predict success probability (Ⅱ‑2A).

The Bishop score is the most widely‑accepted tool for cervical assessment. A score ≥ 6 indicates cervical ripeness; higher scores correlate with higher induction success rates. A score ＜ 6 denotes an unripe cervix requiring cervical‑ripening measures. The Bishop score shall be documented in the medical record (Ⅲ‑B).

4.1 Prostaglandin Preparations for Cervical Ripening

Prostaglandin agents are the mainstay pharmacological options for clinical cervical ripening.

1. Controlled‑release dinoprostone insert This is a controlled‑release prostaglandin E₂ vaginal pessary containing 10 mg dinoprostone, releasing at 0.3 mg/h, requiring refrigerated storage.

(1) Advantages: controlled drug release; easy removal in case of uterine tachysystole.

(2) Administration: After vulvar disinfection, place the insert deep in the posterior fornix, rotate 90° to position it transversely and maintain placement. Leave a 2‑3 cm retrieval tail outside the vaginal introitus for removal. After insertion, keep the patient supine for 20‑30 min to allow hydration and swelling of the pessary. Re‑examine after 2 hours; the patient may ambulate if the insert remains in situ.

(3) Indications for prompt removal: ① Regular uterine contractions (1 contraction every 3 minutes) accompanied by improved cervical ripeness with Bishop score ≥ 6 (Ⅰ). ② Spontaneous or artificial rupture of membranes. ③ Uterine tachysystole (≥5 contractions per 10 minutes; Ⅱ‑1). ④ 24 hours after insertion (Ⅱ‑1). ⑤ Evidence of fetal compromise: decreased/absent or excessive fetal movements; category Ⅱ or Ⅲ cardiotocography tracings. ⑥ Unexplained maternal adverse reactions including nausea, vomiting, diarrhoea, fever, hypotension, tachycardia, or increased vaginal bleeding (Ⅱ‑1). Oxytocin intravenous infusion may commence no earlier than 30 minutes after insert removal (Ⅱ‑1).

(4) Contraindications: asthma, glaucoma, severe hepatic‑renal insufficiency; history of precipitous labour or multiparity with ≥3 term deliveries; scarred uterus (Ⅱ‑2D); history of cervical surgery or cervical laceration; established labour; Bishop score ≥ 6; acute pelvic inflammatory disease; placenta previa or unexplained vaginal bleeding; abnormal fetal lie; suspected fetal distress; ongoing oxytocin infusion; hypersensitivity to dinoprostone or excipients.

2. Misoprostol A synthetic prostaglandin E₁ analogue available in 100 μg and 200 μg tablets. The US Food and Drug Administration (FDA) approved misoprostol for cervical ripening and labour induction in the second trimester in 2002. Although not approved by the FDA or China NMPA for third‑trimester cervical ripening, the American College of Obstetricians and Gynecologists (ACOG) reaffirmed its obstetric use specifications in 2009. Referencing ACOG 2009 guidelines together with domestic clinical experience, the Obstetrics Group, Society of Obstetrics and Gynecology, Chinese Medical Association has formulated clinical protocols for misoprostol‑assisted cervical ripening in late‑pregnancy after repeated expert discussions.

(1) Misoprostol represents a safe and effective induction method for women in late pregnancy with intact membranes and unripe cervix (Ⅰ‑A).

(2) Vaginal dose: 25 μg per application; avoid crushing tablets. If no contractions occur 6 hours post‑application, perform vaginal examination before re‑dosing to reassess cervical status and confirm dissolution and absorption of prior dose; re‑administration is contraindicated if residual tablet material persists. The maximum daily total dose shall not exceed 50 μg to prevent excessive systemic absorption.

(3) Oxytocin infusion may be initiated no less than 4 hours after the final misoprostol vaginal application, and only after vaginal examination confirms misoprostol absorption (Ⅲ‑B).

(4) Patients receiving misoprostol shall be managed in the delivery suite with continuous monitoring of uterine activity and fetal heart rate. In the event of uterine tachysystole, perform immediate vaginal examination and remove residual medication.

(5) Advantages: low cost, chemical stability, convenient storage, prolonged duration of action, suitable for primary‑care‑level facilities. Multiple prospective randomised controlled trials and meta‑analyses support its efficacy for cervical ripening[9‑11]. Most maternal‑fetal adverse events associated with misoprostol correlate with doses exceeding 25 μg per application (Ⅰ).

(6) Contraindications and removal criteria: identical to those for controlled‑release dinoprostone insert.

4.2 Mechanical Cervical‑Ripening Methods

Options include low‑lying water bag, Foley catheter, double‑balloon catheter, laminaria tents. These devices are applied only with intact fetal membranes and absence of vaginal infection. They act via mechanical cervical‑canal stimulation, promoting local endogenous prostaglandin synthesis and release to achieve cervical softening and ripening.

1. Advantages: compared with prostaglandins, lower cost, stable at room temperature, lower risk of uterine tachysystole.
2. Disadvantages: potential risks of infection, premature rupture of membranes, and cervical trauma.

Evidence supports the efficacy of mechanical cervical dilators for women requiring induction with unfavourable cervix; balloon catheter placement prior to oxytocin infusion shortens time‑to‑labour and reduces cesarean‑section rates versus oxytocin alone. Prostaglandin‑only regimens carry higher risks of uterine tachysystole (with or without fetal‑heart‑rate changes).

Ⅴ. Conventional Labor‑Induction Modalities

5.1 Intravenous Oxytocin Infusion

Low‑dose intravenous oxytocin is a safe and widely‑used induction method, though efficacy is limited with unripe cervix. Benefits include titratable dosing to maintain physiological effective uterine contractions, and immediate discontinuation upon adverse events. Oxytocin has a short half‑life of 5‑12 minutes.

1. Protocol: Low‑dose regimens are recommended; infusion pumps are preferred where available. (1) Infusion preparation: Start with 500 mL lactated Ringer’s solution infused via 7‑gauge venous cannula, initial rate set at 8 drops/min. Add 2.5 U oxytocin to the infusion bag, mix thoroughly and commence infusion. Do not premix 2.5 U oxytocin into lactated Ringer’s solution prior to venipuncture, as rapid unregulated drug delivery may occur.
   (2) Concentration and infusion‑rate titration: Owing to wide inter‑individual sensitivity variation, commence at low dose and escalate incrementally. Baseline concentration: 2.5 U oxytocin in 500 mL lactated Ringer’s solution (0.5 % oxytocin). Assuming 15 drops/mL, each drop contains 0.33 mU oxytocin. Initiate at 8 drops/min; adjust according to uterine contractions and fetal heart rate every 20 minutes. Titration sequence: 8 drops/min (2.7 mU/min) → 16 drops/min (5.4 mU/min) → 24 drops/min (8.4 mU/min). For safety, alternatively increase by 4 drops/min until effective contractions are achieved.
   Effective contractions are defined as 3 contractions within 10 minutes, each lasting 30‑60 seconds, accompanied by cervical effacement and dilation. The maximum infusion rate shall not exceed 40 drops/min (13.2 mU/min). If effective labour is not achieved at maximal rate, increase oxytocin concentration while keeping total oxytocin dosage unchanged: add 5 U oxytocin into 500 mL lactated Ringer’s solution (1 % concentration), halve the infusion rate and retitrate. Under higher concentration, upper limit remains 40 drops/min (26.4 mU); further increases in rate or concentration are not permitted.
   (3) Oxytocin‑related adverse effects are dose‑dependent, most commonly uterine tachysystole and fetal‑heart‑rate abnormalities. Uterine tachysystole may result in placental abruption or uterine rupture. Low‑dose slow titration reduces tachysystole associated with fetal‑heart‑rate changes (Ⅲ). High‑dose rapid escalation may shorten labour duration and reduce chorioamnionitis and labour‑dystocia‑related cesarean delivery, yet increase tachysystole with fetal‑heart‑rate alterations (Ⅰ).
2. Precautions (1) Dedicated staff shall continuously document contraction intensity, frequency, duration and fetal‑heart‑rate patterns. Cardiotocography shall be performed once adequate contractions are established. After membrane rupture, assess amniotic‑fluid volume and degree of meconium staining. (2) Monitor for hypersensitivity reactions. (3) Intramuscular, subcutaneous, acupoint and intranasal oxytocin administration are contraindicated. (4) Restrict total fluid input to prevent water intoxication. (5) Discontinue oxytocin promptly for hypertonic uterine activity; tocolytics shall be administered if clinically indicated. (6) Induction failure: Success correlates with cervical ripeness, gestational age and fetal station. If no meaningful progress occurs after 2‑3 consecutive days of oxytocin infusion, switch to alternative induction strategies.

5.2 Artificial Rupture of Membranes (ARM)

Artificial amniotomy releases endogenous prostaglandins and oxytocin to trigger uterine contractions. This intervention is reserved for patients with favourable cervix and engaged cephalic presentation (Ⅲ‑B). The latency interval from ARM to labour onset is unpredictable when used in isolation. Evidence supporting standalone ARM efficacy and safety remains limited. One clinical trial demonstrated that ARM combined with intravenous oxytocin shortens induction‑to‑delivery interval compared with ARM alone (Ⅰ).

Potential risks of ARM include umbilical‑cord prolapse or compression, maternal‑fetal infection, vasa previa rupture and fetal trauma. ARM is contraindicated in women with unengaged fetal head. Vaginal infection must be excluded prior to the procedure. Perform amniotomy during uterine relaxation to avoid cord prolapse or placental abruption secondary to rapid amniotic‑fluid egress. Auscultate fetal heart rate pre‑ and post‑ARM; observe amniotic‑fluid character and fetal‑heart‑rate changes after rupture.

Ⅵ. General Considerations During Labor Induction

1. Strictly follow standard operating procedures; adhere to indications and contraindications. Induction without valid indications is prohibited. Re‑evaluate both indication and induction modality in case of induction failure (Ⅲ‑B).
2. Suspected macrosomia shall not serve as an independent indication for labour induction (Ⅲ‑D).
3. First‑trimester ultrasonography is recommended for all pregnancies to confirm gestational age (Ⅰ‑A).
4. Individualise induction modality, drug dosage and route of administration.
5. Do not arbitrarily modify or escalate medication doses.
6. Perform all procedures accurately.
7. Closely monitor labour progress with comprehensive documentation.
8. Once labour commences, implement routine cardiotocography and continuously interpret tracings.
9. In the event of uterine tachysystole, fetal distress, obstructed labour, impending uterine rupture, amniotic‑fluid embolism or other critical events, execute the following management sequence: (1) Immediately discontinue all labour‑inducing agents. (2) Initiate left‑lateral positioning, supplemental oxygen, and oxytocin‑free intravenous fluid infusion. (3) Administer intravenous tocolytic agents (e.g. ritodrine, magnesium sulfate). (4) Perform vaginal examination to assess labour progress. For suspected fetal distress with intact membranes, perform artificial rupture of membranes to evaluate meconium‑staining status. If risk factors persist despite combined interventions, vaginal delivery is not imminent, or maternal‑fetal status is critical, proceed expeditiously with cesarean section for pregnancy termination.

Expert Panel for Guideline Development and Discussion

Yang Huixia (Peking University First Hospital) Fan Ling (Beijing Obstetrics and Gynecology Hospital, Capital Medical University) Liu Xinghui (West China Second University Hospital, Sichuan University) He Jing (Women’s Hospital, Zhejiang University School of Medicine) Hu Yali (Nanjing Drum Tower Hospital, Nanjing University Medical School) Duan Tao (Shanghai First Maternity and Infant Hospital) Zhang Weiyuan (Beijing Obstetrics and Gynecology Hospital, Capital Medical University) Dong Yue (Peking University First Hospital) Shi Chunyan (Peking University First Hospital) Xu Xianming (Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) Liu Zhe (Peking University First Hospital)

Guideline‑Writing Experts

Liu Zhe (Peking University First Hospital) Yang Huixia (Peking University First Hospital）